Effects of Combined Chelation Treatment with Pyridoxal Isonicotinoyl Hydrazone (PIH) Analogs and Deferoxamine in Hypertransfused Rats and in Iron-Loaded Rat Heart Cells Running Head: Combined PIH analog and DFO Chelation Treatment Heading: Red Cells
نویسندگان
چکیده
Gabriela Link , Prem Ponka, Abraham M Konijn, William Breuer, Z Ioav Cabantchik and Chaim Hershko . Department of Human Nutrition and Metabolism, Hebrew University Hadassah Medical School, Department of Biological Chemistry, Institute of Life Sciences, and Department of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem , Jerusalem, Israel and Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
منابع مشابه
Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Although iron chelation therapy with deferoxamine (DFO) results in improved life expectancy of patients with thalassemia, compliance with parenteral DFO treatment is unsatisfactory, underlining the need for alternative drugs and innovative ways of drug administration. We examined the chelating potential of pyridoxal isonicotinoyl hydrazone (PIH) analogs, alone or in combination with DFO, using ...
متن کاملThe potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Numerous studies have suggested that iron (Fe) chelators such as desferrioxamine (DFO) may be useful antitumor agents (Blatt and Stitely, Cancer Res 47:1749, 1987; Becton and Bryles, Cancer Res 48:7189, 1988). Recent work with several analogues of the lipophilic Fe chelator, pyridoxal isonicotinoyl hydrazone (PIH), indicate that some of these ligands are considerably more efficient than DFO bot...
متن کاملThe iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Iron chelating agents are essential for treating iron overload in diseases such as beta-thalassemia and are potentially useful for therapy in non-iron overload conditions, including free radical mediated tissue injury. Deferoxamine (DFO), the only drug available for iron chelation therapy, has a number of disadvantages (e.g., lack of intestinal absorption and high cost). The tridentate chelator...
متن کاملIron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
The chelator currently used to treat iron (Fe) overload disease, desferrioxamine (DFO), has shown anti-proliferative activity against leukemia and neuroblastoma cells in vitro, in vivo and in clinical trials. Collectively, these studies suggest that Fe-deprivation may be a useful anti-cancer strategy. However, the efficacy of DFO is severely limited due to its poor ability to permeate cell memb...
متن کاملThe iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate.
Pyridoxal isonicotinoyl hydrazone (PIH) is able to prevent iron-mediated hydroxyl radical formation by means of iron chelation and inhibition of redox cycling of the metal. In this study, we investigated the effect of PIH on Fe(II)-citrate-mediated lipid peroxidation and damage to isolated rat liver mitochondria. Lipid peroxidation was quantified by the production of thiobarbituric acid-reactiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2002